МЕЛАТОНІН: МЕХАНІЗМИ РЕГУЛЯЦІЇ АРТЕРІАЛЬНОГО ТИСКУ

Cipolla-Neto J, Amaral FGD. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990-1028.

Simko F, Baka T, Krajcirovicova K, et al. Effect of melatonin on the renin-angiotensin-aldosterone system in l-NAME-induced hypertension. Molecules. 2018;23(2):265.

Nikolaev G, Robeva R, Konakchieva R. Membrane melatonin receptors activated cell signaling in physiology and disease. Int J Mol Sci. 2021;23(1):471.

Costantino S, Paneni F, Cosentino F. Ageing, metabolism and cardiovascular disease. J Physiol. 2016;594(8):2061-2073.

Ashour AM. The effect of melatonin supplement on high arterial blood pressure: An overview from Clinicaltrials.gov. J Multidiscip Healthc. 2024;17:517-520.

Abdulqader BK. Effect of endogenous melatonin hormone on cardiovascular system: A review of literature. Ann Coll Med Mosul. 2023;45(1):84-91.

Wang YQ, Jiang YJ, Zou MS, et al. Antidepressant actions of melatonin and melatonin receptor agonist: Focus on pathophysiology and treatment. Behav Brain Res. 2022;420:113724.

Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood pressure regulation and patterning. Sleep Med Rev. 2017;33:4-16.

Campos LA, Baltatu OC, Senar S, et al. Multiplatform-integrated identification of melatonin targets for a triad of psychosocial-sleep/circadian-cardiometabolic disorders. Int J Mol Sci. 2023;24(1):860.

Ishigaki S, Ohashi N, Isobe S, et al. Impaired endogenous nighttime melatonin secretion relates to intrarenal renin-angiotensin system activation and renal damage in patients with chronic kidney disease. Clin Exp Nephrol. 2016;20(6):878-884.

Cherkas A, Abrahamovych O, Golota S, et al. The correlations of glycated hemoglobin and carbohydrate metabolism parameters with heart rate variability in apparently healthy sedentary young male subjects. Redox Biology. 2015;5:301-307.

Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.

Huang QF, Yang WY, Asayama K, et al. Ambulatory blood pressure monitoring to diagnose and manage hypertension. Hypertension. 2021;77(2):254-264.

Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci. 2014;15(10):17920-37.

Lumsden SC, Clarkson AN, Cakmak YO. Neuromodulation of the pineal gland via electrical stimulation of its sympathetic innervation pathway. Front Neurosci. 2020;14:264.

Repova K, Baka T, Krajcirovicova K, et al. Melatonin as a potential approach to anxiety treatment. Int J Mol Sci. 2022;23(24):16187.

Simko F, Baka T, Paulis L, et al. Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review. J Pineal Res. 2016;61(2):127-37.

Nishi EE, Almeida VR, Amaral FG, et al. Melatonin attenuates renal sympathetic overactivity and reactive oxygen species in the brain in neurogenic hypertension. Hypertens Res. 2019;42(11):1683-1691.

Jiao L, Wang Y, Zhang S, et al. Melatonin improves cardiac remodeling and brain-heart sympathetic hyperactivation aggravated by light disruption after myocardial infarction. J Pineal Res. 2022;73(4):e12829.

Cherkas A, Eckl P, Gueraud F, et al. Helicobacter pylori in sedentary men is linked to higher heart rate, sympathetic activity, and insulin resistance but not inflammation or oxidative stress. Croat Med J. 2016;57(2):141-149.

Serhiyenko V, Serhiyenko A, Segin V, et al. Association of arterial stiffness, N-terminal pro-brain natriuretic peptide, insulin resistance, and left ventricular diastolic dysfunction with diabetic cardiac autonomic neuropathy. Vessel Plus. 2022;6:11.

Martinez A, Lakkimsetti M, Maharjan S, et al. Beta-blockers and their current role in maternal and neonatal health: A narrative review of the literature. Cureus. 2023;15(8):e44043.

Tobeiha M, Jafari A, Fadaei S, et al. Evidence for the benefits of melatonin in cardiovascular disease. Front Cardiovasc Med. 2022;9:888319.

Langston-Cox A, Marshall SA, Lu D, et al. Melatonin for the management of preeclampsia: A review. Antioxidants (Basel). 2021;10(3):376.

Reiter RJ, Sharma R, Chuffa LGA, et al. Mitochondrial melatonin: beneficial effects in protecting against heart failure. Life (Basel). 2024;14(1):88.

Di Santo P, Mathew R, Jung RG, et al.; CAPITAL DOREMI investigators. Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. Crit Care. 2021;25(1):289.

Hoseini SG, Heshmat-Ghahdarijani K, Khosrawi S, et al. Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial. Clin Cardiol. 2022;45(4):417-426.

Anghel L, Baroiu L, Popazu CR, et al. Benefits and adverse events of melatonin use in the elderly (Review). Exp Ther Med. 2022;23(3):219.

Xie Z, Chen F, Li WA, et al. A review of sleep disorders and melatonin. Neurol Res. 2017;39(6):559-565.

Serhiyenko VA, Serhiyenko LM, Sehin VB, et al. Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview. Endocr Regul. 2022;56(4):284-294.

Ozkalayci F, Kocabas U, Altun BU, et al. Relationship between melatonin and cardiovascular disease. Cureus. 2021;13(1):e12935.

Lee EK, Poon P, Yu CP, et al. Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2022;24(5):529-535.

Rexhaj E, Pireva A, Paoloni-Giacobino A, et al. Prevention of vascular dysfunction and arterial hypertension in mice generated by assisted reproductive technologies by addition of melatonin to culture media. Am J Physiol Heart Circ Physiol. 2015;309(7):H1151-H1156.

Cvikova D, Sutovska H, Babarikova K, et al. Hypotensive effects of melatonin in rats: Focus on the model, measurement, application, and main mechanisms. Hypertens Res. 2022;45(12):1929-1944.

Kim H, Jung HR, Kim JB, et al. Autonomic dysfunction in sleep disorders: from neurobiological basis to potential therapeutic approaches. J Clin Neurol. 2022;18(2):140-151.

Hadi A, Ghaedi E, Moradi S, et al. Effects of melatonin supplementation on blood pressure: a systematic review and metaanalysis of randomized controlled trials. Horm Metab Res. 2019;51(3):157-164.

Amstrup AK, Rejnmark L. Effects of melatonin on blood pressure, arterial stiffness and quality of life in postmenopausal women: A randomized controlled trial. Complement Ther Med. 2024;81:103026.

Raygan F, Ostadmohammadi V, Bahmani F, et al. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(1):191-196.

Goyal A, Terry PD, Superak HM, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014;6:124.

Agahi M, Akasheh N, Ahmadvand A, et al. Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial. Diabetes Metab Syndr. 2018;12(1):9-15.

Baker J. Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent. Clin Exp Pharmacol Physiol. 2018;45(8):755-766.

Vancampfort D, Rosenbaum S, Ward PB, et al. Type 2 diabetes among people with posttraumatic stress disorder: systematic review and meta-analysis. Psychosom Med. 2016;78(4):465-473.

Ziegler D, Porta M, Papanas N, et al. The role of biofactors in diabetic microvascular complications. Curr Diabetes Rev. 2022;18(4):e250821195830.

Możdżan M, Możdżan M, Chałubiński M, et al. The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension. Arch Med Sci. 2014;10(4):669-75.

Bazyar H, Zare Javid A, Bavi Behbahani H, et al. Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial. Trials. 2021;22(1):231.

Pourhanifeh MH, Hosseinzadeh A, Dehdashtian E, et al. Melatonin: new insights on its therapeutic properties in diabetic complications. Diabetol Metab Syndr. 2020;12:30.

Harpsøe NG, Andersen LP, Gögenur I, et al. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-9.

Vural EM, van Munster BC, de Rooij SE. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging. 2014;31(6):441-51.

Rahbari-Oskoui FF, Abramson JL, Bruckman AM, et al. Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure: Results from a preliminary randomized, crossover trial. Complement Ther Med. 2019;43:157-164.

Fatemeh G, Sajjad M, Niloufar R, et al. Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2022 Jan;269(1):205-216.

Kara H, Kara A. Melatonin in cardiovascular diseases. In: Gelen V, editors. Melatonin - recent updates. London, UK: IntechOpen; 2022. pp. 74-105.